IFNB1 and glioma: The human F3 NSCs cell line has been used in multiple studies to perform NSC-based gene therapy, delivering both IFN-β and cytosine deaminase (CD)/5-fluorocytosine (5-FC) prodrugs to glioma cells (Dickson et al. 2007; Kim et al. 2006; Shimato et al. 2007).